Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

  • Sigilon Therapeutics (NASDAQ:SGTX) stock rose 15.5% to $1.49 during Monday's after-market session. The market value of their outstanding shares is at $48.1 million.
  • Esperion Therapeutics (NASDAQ:ESPR) shares moved upwards by 10.33% to $5.23. The company's market cap stands at $328.5 million.
  • Terns Pharma (NASDAQ:TERN) stock rose 8.33% to $3.25. The market value of their outstanding shares is at $82.1 million.
  • Cano Health (NYSE:CANO) shares rose 7.34% to $5.7. At the close, Cano Health's trading volume reached 119.7K shares. This is 3.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q4 earnings report came out today.
  • Midatech Pharma (NASDAQ:MTP) stock increased by 6.95% to $0.92. The market value of their outstanding shares is at $11.6 million.
  • Soleno Therapeutics (NASDAQ:SLNO) stock rose 6.62% to $0.28. The market value of their outstanding shares is at $22.7 million.

Losers

  • AnaptysBio (NASDAQ:ANAB) shares fell 11.9% to $25.06 during Monday's after-market session. The company's market cap stands at $693.4 million.
  • Incannex Healthcare (NASDAQ:IXHL) stock fell 11.53% to $85.0. The market value of their outstanding shares is at $4.1 billion.
  • Better Therapeutics (NASDAQ:BTTX) shares declined by 7.41% to $3.75. The market value of their outstanding shares is at $88.4 million.
  • 180 Life Sciences (NASDAQ:ATNF) shares fell 6.37% to $2.5. The market value of their outstanding shares is at $85.0 million.
  • Tenax Therapeutics (NASDAQ:TENX) shares fell 5.01% to $0.51. The company's market cap stands at $12.8 million.
  • Sunshine Biopharma (NASDAQ:SBFM) stock decreased by 4.9% to $2.72. The market value of their outstanding shares is at $12.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.